Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 76.74% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Truist Financial lifted their price objective on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. BTIG Research lifted their price target on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $49.50.

Genmab A/S Stock Up 0.3 %

Shares of NASDAQ GMAB opened at $28.29 on Thursday. The stock has a market capitalization of $18.71 billion, a price-to-earnings ratio of 23.58, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97. Genmab A/S has a 52 week low of $24.53 and a 52 week high of $41.58. The firm has a 50-day moving average price of $26.96 and a 200 day moving average price of $28.33.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The company had revenue of $603.30 million during the quarter, compared to the consensus estimate of $594.23 million. Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. Equities research analysts expect that Genmab A/S will post 1.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently modified their holdings of the company. Ingalls & Snyder LLC lifted its stake in shares of Genmab A/S by 29.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock worth $5,772,000 after purchasing an additional 52,117 shares during the period. Crossmark Global Holdings Inc. boosted its stake in Genmab A/S by 11.4% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 70,632 shares of the company’s stock worth $1,775,000 after buying an additional 7,242 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Genmab A/S by 123.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock valued at $81,000 after acquiring an additional 1,787 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Genmab A/S by 4.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock valued at $1,763,000 after acquiring an additional 3,283 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Genmab A/S by 22.8% during the 2nd quarter. SG Americas Securities LLC now owns 36,234 shares of the company’s stock worth $911,000 after acquiring an additional 6,734 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.